在心房中重新考虑迪戈辛:从历史争议到生理学指导和个性化节拍控制
Silvia Ana Luca1,2,3,4, Adelina Andreea Faur-Grigori1,2,3, Cristina Văcărescu2,3,4
1Doctoral School, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timișoara, Romania.
Biomedicines
|December 30, 2025
概括
当正确剂量和监测时,滴毒素是心力衰竭患者心房动的安全有效治疗方法. 它的安全性和有效性取决于保持低血清度以避免毒性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学 是一个学科.
背景情况:
- 在心力衰竭 (HF) 的心房动 (AF) 中使用狄戈辛是有争议的,因为观察性研究表明死亡率增加.
- 关于狄戈辛安全性的担忧往往归因于诸如处方偏差和血清水平调整不足等混因素,而不是内在的毒性.
研究的目的:
- 根据当前的证据,重新评估狄戈辛在HF的AF中的作用.
- 提出一个个性化,基于生理学的监测框架,用于狄戈辛治疗.
主要方法:
- 重新分析将狄戈辛与死亡率联系在一起的研究,使用随机证据,偏差解构和暴露-反应分析.
- 评估血清狄戈辛度与临床结果之间的关联.
主要成果:
- 低血清狄戈辛度与有效控制AF发病率而没有增加死亡率有关.
- 迪戈辛是一种安全的二线选择,用于控制低血压或不耐受β阻断剂的HF患者的AF率.
- 副作用与较高的血清狄戈辛水平 (≥1.2 ng/mL) 相关联;心率作为监测指标.
结论:
- 正确剂量和监测的迪戈辛是一种安全,有效和个性化的AF在HF的速率控制剂.
- 基于概率的监测模型和"药丸在口袋里"的策略需要进一步研究,以优化狄戈辛的管理.
相关概念视频
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K
Dysrhythmias VI: Management of Dysrhythmias
385
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
385
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.8K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.7K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K


